REG - Scancell Hlds - Presenting at the Annual Immuno-Oncology Summit

Scancell HoldingsAnnouncement

17/04/2024 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240417:nRSQ8760Ka&default-theme=true

RNS Number : 8760K  Scancell Holdings Plc  17 April 2024

17 April 2024

 

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell to present at the Annual Immuno-Oncology Summit Europe

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer, announces that it will be presenting at the 8(th)
Immuno-Oncology Summit Europe 2024. The Immuno-Oncology Summit Europe is a
world-class event for professionals dedicated to showcasing advancements and
innovations in immuno-oncology for breakthrough therapies, and is being held
from 23-25 April 2024 in London, UK.

 

Professor Lindy Durrant, Chief Executive Officer of Scancell, will be speaking
in the "Therapeutic Cancer Vaccines" program, where emphasis on clinical
studies will be highlighted as part of a broader collection of talks
furthering understanding of immunological mechanisms of action, dosing and
delivery strategies as well as how such products can be combined with
checkpoint inhibitors. Her talk, titled "Clinical Update on the DC Targeting
Melanoma Vaccine, SCIB1 and The Modi-1 Vaccine Targeting Citrullination" will
take place from 2:45 pm - 3:15 pm BST on Tuesday 23 April 2024.

 

Professor Lindy Durrant, Chief Executive Officer of Scancell, said: "I am
pleased to be invited to share this exciting data on SCIB1, Scancell's 'off
the shelf' ImmunoBody(®) cancer vaccine, which has demonstrated positive
efficacy data from the Phase 2 SCOPE trial for advanced unresectable melanoma.
I am also looking forward to presenting early data from patients receiving
Modi-1 as a monotherapy in range of hard-to-treat solid tumours, which has
shown good T cell responses, safety and tolerability. Following on from AACR,
there has been significant interest in the clinical development of therapeutic
cancer vaccines, and I am excited to demonstrate the progress Scancell has
made in this class of immunotherapies."

 

 

If you would like to arrange a meeting with management, please contact
commercial.enquiries@scancell.co.uk
(mailto:commercial.enquiries@scancell.co.uk) .

 

-ENDS-

 

 For further information, please contact:
 Scancell Holdings plc                                                +44 (0) 20 3709 5700
 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)  +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 WG Partners LLP (Joint Broker)                                       +44 (0) 20 3705 9330
 David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

 Panmure Gordon (UK) Limited (Joint Broker)                           +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 

 ICR Consilium                                  +44 (0) 20 3709 5700
 Mary-Jane Elliott/Angela Gray/Lindsey Neville  scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCIFMPTMTABBMI